Kagocel+Valacyclovir; Valacyclovir
Проводит Nearmedic Plus LLC
Страница компанииClinical and Immunological Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection) by Acyclic Nucleoside Valacyclovir and Interferon Inducer Kagocel
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04664127/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 45 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (10.2018) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 8
Критерии включения
- Patients ≥ 18 years old
- The absence of systemic etiotropic antiviral and immunosuppressive therapy for at least a year at the time of inclusion in this study
- Severe herpes simplex (HSV infection with orolabial and / or genital localization) with a recurrence rate of 6 or more for last 12 months.
- The first 6-48 hours after the exacerbation of herpes simplex.
- The following diseases and conditions are missing, usually requiring combination therapy by more than 2 drugs: ophthalmic herpes, visceral herpes, herpetic encephalitis, Kaposi's herpetiform eczema, primary immunodeficiency (PID criteria are given below*), tuberculosis, ARVI and influenza symptoms (not related to herpesviruses), diabetes mellitus, hepatitis B and/or C, autoimmune diseases, HIV infection, other diseases requiring specific treatment (syphilis, gonorrhea), septic conditions, cancer (except of benign skin growths), mental illness, alcohol and/or drug addiction, artificial radiation and/or radiation therapy.
- Standard Valacyclovir therapy prescribed by doctor, or combination therapy by Valacyclovir and Kagocel.
Критерии невключения
- Basic cytostatic therapy, taking systemic glucocorticoids for life indications. Treatment by immunoglobulins and any vaccines for 30 days prior to inclusion in the study.
- Early period (up to 1 month) after any vaccination.
- Pregnancy, including pregnancy planning for 3 months and lactation.
- The presence of a genetic disease or verified primary immunodeficiency.
- Anamnesis of transplantation of organs and tissues.
- Plasmapheresis and blood donation for less than 6 months before the present study.
- Severe kidney and liver damage.
- Any other diseases or conditions that, by the opinion of the researcher, may interfere the patient from being included in the study.
Источник: ClinicalTrials.gov, NCT04664127 · запись обновлена в реестре 11 декабря 2020.
Дизайн и результаты
Что измеряют — первичные конечные точки (4), вторичных — 11
- Change of the patients proportion with different localizations of herpes simplex exacerbations. — 2 points: before and 6 months after the start of therapy
- Change of the rate of exacerbations of orolabial, genital and other localization herpes simplex — 2 points: before and 6 months after the start of antiviral therapy
- Change of the number of patients with varying degrees of severity illness — 2 points: before and 6 months after the start of therapy
- Change in the number of local complaints (pain, itching, burning, rash) against the background of a recurrence of herpes simplex — up to 6 months
Цель исследования
This study examined the efficacy, safety and benefits of modern treatment and changes in the dynamics of the life of adult patients quality with severe herpes simplex in the current medical practice when combined therapy by acyclic nucleoside Valacyclovir and antiviral agent Kagocel versus monotherapy by Valacyclovir. This study also evaluated the structure of herpesvirus infections and the rate of mixed variants of the course, the rate of exacerbations of herpes simplex, the time of disappearance of human herpesvirus isolation and the features of the immune phenotype of patients taking different types of therapy.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04664127 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.